Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
US Oncology Research Ortho Biotech Products, L.P. Tibotec Pharmaceutical Limited |
---|---|
Information provided by: | US Oncology Research |
ClinicalTrials.gov Identifier: | NCT00303108 |
The purpose of this study is to determine the ORR associated with Doxil in combination with carboplatin in HER2- (negative) MBC (and with Herceptin in HER2+ MBC).
Condition | Intervention | Phase |
---|---|---|
Metastatic Breast Cancer |
Drug: Doxil Drug: Carboplatin Drug: Herceptin |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Parallel Assignment, Efficacy Study |
Official Title: | Phase II Study of Doxil and Carboplatin, Plus Herceptin in HER2+ Patients, in Metastatic Breast Cancer |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Maria Crockett | 832-601-5915 | Maria.Crockett@USOncology.com |
Contact: Laura Guerra | 832-601-5275 | Laura.Guerra@USOncology.com |
Principal Investigator: | Rufus P Collea, MD | US Oncology Research |
Study ID Numbers: | 04111 |
Study First Received: | March 13, 2006 |
Last Updated: | August 17, 2007 |
ClinicalTrials.gov Identifier: | NCT00303108 |
Health Authority: | United States: Food and Drug Administration |
Skin Diseases Trastuzumab Breast Neoplasms |
Carboplatin Doxorubicin Breast Diseases |
Neoplasms Neoplasms by Site Antineoplastic Agents |
Therapeutic Uses Antibiotics, Antineoplastic Pharmacologic Actions |